• Mycobacterium tuberculosis and the response of its host
• 34 min
  1. The genetic structure of Mycobacterium tuberculosis - insights into genome organisation and evolution of the causative agent of tuberculosis

  • Dr. Roland Brosch
• 36 min
  2. The pathogenesis of tuberculosis

  • Dr. William R. Bishai
• 57 min
  3. Immune response and rational development of vaccines and biomarkers

  • Prof. Dr. Stefan H. E. Kaufmann
• 38 min
  4. Molecular mechanisms of drug resistance in M. tuberculosis

  • Dr. Daniela Cirillo
• The epidemiology of tuberculosis
• 40 min
  5. The basic epidemiology of tuberculosis (TB)

  • Dr. David Dowdy
• 34 min
  6. Global epidemiology of TB

  • Dr. Philippe Glaziou
• 48 min
  7. Social determinants of tuberculosis

  • Dr. Knut Lönnroth
• The control of tuberculosis
• 46 min
  8. Treatment of tuberculosis

  • Dr. Jean-Pierre Zellweger
• 32 min
  9. The End TB Strategy towards TB elimination 1

  • Dr. Mario Raviglione
• 52 min
  10. The End TB Strategy towards TB elimination 2

  • Dr. Mario Raviglione
• 38 min
  11. Financing TB care and control

  • Dr. Christopher Fitzpatrick
  • Dr. Andrea Pantoja
• 27 min
  12. Tuberculosis and COVID-19

  • Prof. Giovanni Battista Migliori
• 36 min
  13. Multidrug resistant tuberculosis (MDR-TB): an update

  • Dr. Simon Tiberi
• 49 min
  14. Impact of HIV on tuberculosis in the developing world and how to manage it

  • Prof. Anthony D. Harries
• 33 min
  15. Reaching the missing millions through public-private mix (PPM) for TB prevention and care

  • Ms. Hannah Monica Dias
• 39 min
  16. TB in children

  • Prof. Ben J. Marais
• 30 min
  17. Community engagement in tuberculosis care

  • Ms. Lana Syed
• 29 min
  18. India: the epicentre of global TB control

  • Dr. Madhukar Pai
• 23 min
  19. Community engagement in TB care

  • Dr. Haileyesus Getahun
• Research and development for new approaches in the control of tuberculosis
• 21 min
  20. Development of new regimens for tuberculosis

  • Dr. Zhenkun Ma
• 35 min
  21. Development, testing and introduction of new diagnostic tools for tuberculosis

  • Dr. Mark Perkins
• 69 min
  22. Pharmacometrics in tuberculosis

  • Prof. Charles A. Peloquin
• 29 min
  23. Extrapulmonary tuberculosis

  • Dr. Scott Heysell
• 27 min
  24. The role of surgery in tuberculosis management

  • Dr. Richard Zaleskis
• Archived Lectures *These may not cover the latest advances in the field
• 28 min
  25. The development of current treatments for tuberculosis

  • Dr. Andrew Nunn
• 47 min
  26. The pathogenesis of tuberculosis

  • Dr. William R. Bishai
• 34 min
  27. Basics of tuberculosis epidemiology

  • Prof. Frank Cobelens
• 40 min
  28. Drug resistance in tuberculosis and its public health management

  • Dr. Paul Nunn
• 57 min
  29. The international approach to the control of tuberculosis

  • Dr. Mario Raviglione
• 35 min
  30. Public-private mix for TB care and control

  • Dr. Mukund Uplekar

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Overview
3. The global burden of TB - 2010
4. TB incidence rates - 2010
5. Impact of HIV on TB in Africa
6. % MDR-TB among new TB cases 1994-2009
7. Absolute numbers of reported MDR-TB cases
8. 13 top settings with highest % of MDR-TB
9. Time trends in TB and MDR-TB
10. Countries with at least one XDR-TB case
11. Progress towards international targets
12. Stop TB strategy and global plan
13. The global TB control targets
14. Achievements thus far, 2011
15. Incidence, prevalence and mortality rates
16. Reductions in TB cases and deaths in China
17. TB cases and deaths, absolute numbers
18. Notifications of MDR-TB increasing
19. Case notifications by region, 1990-2010
20. Global notifications
21. Challenges in 2011
22. Challenges in 2011 if we target "elimination"
23. Funding required, global plan
24. Underfunding persists
25. Funding for TB control increasing
26. BRICS mostly domestic funding
27. HIV testing for TB patients expanding
28. CPT and ART for HIV+ TB patients
29. Policy on collaborative TB/HIV activities
30. Treatment success 87% globally
31. TB patients tested for MDR-TB remain low
32. Response to M/XDR-TB in 27 HBCs
33. Critical steps for prevention and control
34. Policy changes are fundamental
35. Increasing notifications via PPM
36. Increasing case notifications is good
37. Limitations of diagnostics, drugs and vaccine
38. 2015 MDG target reached but TB not eliminated
39. Actions needed
40. Tuberculosis control and elimination
41. Innovative action needed in 4 spheres
42. Population attributable fraction
43. Potential impact of new TB vaccines
44. A step ahead in diagnosis: introducing GeneXpert
45. Roll-out of Xpert MTB/RIF
46. Current TB therapy and unmet needs
47. Global TB drug pipeline, June 2011
48. Conclusions
49. Many thanks to all

Topics Covered

• Burden of tuberculosis
• HIV-associated tuberculosis and multidrug-resistant tuberculosis
• Progress towards achievement of international targets
• Challenges in 2012
• Interventions needed in four areas; intensification of core tuberculosis control and care efforts, bold health policies, increased research efforts, and alleviation of socio-economic determinants of tuberculosis

Links

Series:

• Tuberculosis

Categories:

• Microbiology

Therapeutic Areas:

• Infectious Diseases
• Respiratory Diseases

Talk Citation

Publication History

• Published on February 28, 2013
• Archived on November 30, 2021

Financial Disclosures

• Dr. Mario Raviglione has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.